Top Tech Companies (113)
Don't see your company?
Create a company profile
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
QIO Technologies is a sustainability tech company delivering Industrial IoT AI software products supporting energy-intensive and asset-heavy Industrial, Data Center and Telecom companies to reduce greenhouse gas emissions, improve energy efficiency, and accelerate operational sustainability. QiO developed its Foresight Sustainability Suite™ in response to the difficulties faced by industry in leveraging large, disparate sources of operational data to reduce GHG emissions and improve operational efficiency. By applying its AI optimisation technology in sectors ranging from automotive, steel, glass, cement, oil & gas, data centers and telecoms, Foresight Sustainability Suite™ has delivered up to 20% savings on energy and maintenance costs and reduced GHG emissions by up to 10%. QiO’s newest product, Foresight Optima DC+™, was developed in partnership with Intel to meet the needs of energy-intensive data centers. Foresight Optima DC+™ has delivered energy savings and emissions reductions of up to 50% in data centers worldwide by analysing energy consumption and making real-time adjustments to individual servers. QiO’s Foresight Sustainability Suite™ operates by collecting data from industrial assets ranging from kilns, furnaces, boilers and compressors to cooling systems and data center servers. Using AI, Foresight Sustainability Suite™ identifies and implements real-time actions that optimise energy efficiency and resource use, helping customers make rapid reductions in GHG emissions, energy use, production costs and waste. With businesses under pressure to meet international sustainability reporting standards, Foresight Sustainability Suite™ also automates real-time ESG reporting, enabling every customer to track and report Scope 1 and Scope 2 emissions.
All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.
BlakBear tells you how fresh your food is. We replace shelf-life on fish and meat with a sensor that actually knows. Founded by scientists from Imperial College, we sell freshness sensors and a cloud API, to improve quality control, add shelf-life and cut food waste from producer to consumer.
Hidden within our planet's vast biodiversity are solutions to some of humanity's greatest challenges, with the potential to deliver sustainable food supplies, revolutionary manufacturing capabilities, and a new generation of medicines. At Basecamp Research, we are building BaseDiscovery, a platform technology that will use next-gen DNA analysis and environmental monitoring to connect the dots and improve our understanding of the natural world. Our team uses a unique and fully portable laboratory capable of rapidly analysing nature anywhere on Earth, discovering novel solutions to the world's most pressing challenges
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time. Our advisors and partners include leading academics and providers in the fields of quantum computing, AI and machine learning and drug discovery. In addition to our in-house discovery programs, we are interested in drug discovery collaborations with pharmaceutical and biotech companies seeking new approaches to novel, first in class, best in class or next generation inhibitors for validated or intractable enzyme targets.
SIME is a clinical AI company applying medical excellence, proprietary AI and data ingenuity to deliver rapid respiratory intensive care diagnostics for acute unmet needs. Our clinically proven technology enables early intervention in life-threatening diseases - improving outcomes and reducing costs.
Entia is an oncology service provider supporting more effective cancer care by predicting and preventing treatment side effects. Our unique remote patient monitoring solutions, including the world's first at-home full blood count analyser, identify patients at risk of complications early on and enable timely interventions that can result in more time on treatment, fewer unplanned hospitalisations and the potential deliver better survival outcomes. We're proud to be partnered with some of the largest global oncology centres and supporting blockbuster therapies from industry leaders. Together, we're unlocking the full potential of cancer therapy.
Pangaea Data is London and South San Francisco based provider of a software product platform to help healthcare and pharmaceutical providers to find untreated patients and bring them into screening. Such untreated patients include undiagnosed, misdiagnosed, miscoded , uncontrolled and at risk patients who comprise up-to 90% of the patient population across hard to diagnose conditions. Pangaea achieves so by mimicking a clinician's manual process to achieve the same based on clinical guidelines so the results are explainable for clinicians and there is zero disruption for clinical and IT teams. The founders at Pangaea have secured more than $300 million in research funding through their work, which includes a $110 million grant to apply Large Language Models (LLMs) in Medicine. All customer success stories and peer-reviewed publications are available through Pangaea's website.
We started Samphire Neuroscience to build a world where women everywhere have access to scientifically validated wearable technology for their health needs, without having to sacrifice on technology, design or lifestyle. Building on more than thirty years of research and clinical experience, we are developing wearable neurotechnology, the Samphire Headband, that addresses a range of menstrual-cycle related challenges. Want to know more? Reach out to us via [email protected]
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom
Biocentis is an Imperial College London spin-out on a mission to develop eco-friendly genetic solutions to effectively and safely control the dangerous insect species that spread disease to humans, reduce biodiversity, or threaten food security. We leverage CRISPR to develop self-limiting gene drive technologies that are biological, environmentally friendly, and can be tailored to obtain levels of control that are suitable for a broad range of applications. Building on a unique proprietary technological platform, invented by our founders at Imperial College London and applicable to all insect species, Biocentis aims to re-imagine the future of biocontrol. We want to empower communities around the world to tackle the most dangerous insect vectors of disease, to preserve biodiversity and to protect agricultural crops from harmful insect pests. Our vision is a more sustainable world, capable of feeding a growing population and free of vector-borne disease. With offices in Milan and London and a presence in the US, we employ a diverse and accomplished team with unparalleled experience in the scientific and technological fields and an outstanding track record in company building and management. We are also growing very fast, and we encourage you to reach out if you want to be part of our journey.
